UBC formulation of leishmaniasis drug shown to be stable, effective in tropical temperatures

December 07, 2010

A new formulation of Amphotericin B (AmB) developed by University of British Columbia researchers has been shown to be stable in tropical climates and effective in treating Visceral Leishmaniasis (VL) in mouse models.

VL is a blood-born parasitic disease that afflicts 12 million people worldwide, mainly in developing countries and tropical regions. According to the World Health Organization (WHO), 1.5 million new cases of the disease are reported every year, and 60,000 people die from it.

AmB, a 50-year-old anti-fungal drug, is the standard treatment for VL, but its current formulation requires intravenous administration and constant refrigeration, making it costly and challenging to deliver in tropical regions, where VL takes the heaviest toll.

A lipid-based formulation, co-developed by UBC Pharmaceutical Sciences Professor Kishor Wasan and Adjunct Professor Ellen Wasan, allows the drug to be taken orally. It was licensed to Vancouver-based iCo Therapeutics in 2008. As part of the licensing agreement, and in accordance with UBC's Global Access principles, iCo Therapeutics agrees to provide the drug at subsidized costs to developing countries for the treatment of VL.

A new study published today in the online journal PLoS Neglected Tropical Diseases shows that the formulation, called iCo-010, is stable in WHO Climate Zones 3 and 4 (30-43 degrees Celsius) and is efficacious in treating mice with VL.

"In most places where VL is a problem, there is little infrastructure for refrigeration of drug products," says Kishor Wasan, Distinguished University Scholar and co-author of the study. "Now we've shown for the first time this lipid-based formulation can stand up to the harsh conditions of the tropical climate and is effective in animal models when taken orally."

"The development of this thermally stable and efficacious oral formulation brings us one step closer to helping people in remote areas of India, Bangladesh, Nepal and Sudan, where VL is a serious problem," says Ellen Wasan, lead author of the PLoS-NTD paper. Ellen Wasan is an adjunct professor at UBC's Faculty of Pharmaceutical Sciences and a faculty member at the British Columbia Institute of Technology.

The AmB oral formulation is a founding project of the Neglected Global Diseases Initiative (NGDI) at UBC and is funded by the Consortium for Parasitic Drug Development, a grantee of the Bill and Melinda Gates Foundation. Since its launch in 2009, NGDI-associated researchers have received more than $9 million in funding for projects aimed at improving health outcomes for the world's poorest people.
-end-
The Neglected Global Diseases Initiative at UBC (NGDI-UBC) aims to bring together the technical expertise and perspectives of a variety of disciplines at UBC - including bench science, pharmaceutical and health research, business, social policy, and law - to develop interventions for neglected global diseases and ensure their delivery to those in need. For more information, visit www.ngdi.ubc.ca.

University of British Columbia

Related Disease Articles from Brightsurf:

CLCN6 identified as disease gene for a severe form of lysosomal neurodegenerative disease
A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder.

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

Potential link for Alzheimer's disease and common brain disease that mimics its symptoms
A new study by investigators from Brigham and Women's Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer's symptoms.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Tools used to study human disease reveal coral disease risk factors
In a study published in Scientific Reports, a team of international researchers led by University of Hawai'i (UH) at Mānoa postdoctoral fellow Jamie Caldwell used a statistical technique typically employed in human epidemiology to determine the ecological risk factors affecting the prevalence of two coral diseases--growth anomalies, abnormalities like coral tumors, and white syndromes, infectious diseases similar to flesh eating bacteria.

Disease-aggravating mutation found in a mouse model of neonatal mitochondrial disease
The new mitochondrial DNA (mtDNA) variant drastically speeds up the disease progression in a mouse model of GRACILE syndrome.

Human longevity largest study of its kind shows early detection of disease & disease risks
Human Longevity, Inc. (HLI) announced the publication of a ground-breaking study in the journal Proceedings of the National Academy of Sciences (PNAS).

30-year study identifies need of disease-modifying therapies for maple syrup urine disease
A new study analyzes 30 years of patient data and details the clinical course of 184 individuals with genetically diverse forms of Maple Syrup Urine Disease (MSUD), which is among the most volatile and dangerous inherited metabolic disorders.

Long-dormant disease becomes most dominant foliar disease in New York onion crops
Until recently, Stemphylium leaf blight has been considered a minor foliar disease as it has not done much damage in New York since the early 1990s.

Read More: Disease News and Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.